Clinical trial · Interventional
Intra-Ovarian PRP Compared With Gonadotropin for Ovarian Response in Letrozole-Resistant PCOS
Effect of Intra-Ovarian Injection of Autologous Platelet Rich Plasma Compared to Gonadotropin on Ovarian Response in Letrozole Resistant Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this randomized clinical trial is to compare autologous platelet-rich plasma (PRP) with gonadotropin for improving ovarian response in women with letrozole-resistant polycystic ovary syndrome (PCOS). Researchers will compare the two treatments to assess ovarian response, ovulation rates, and pregnancy rates. Participants will be randomly assigned to receive either intra-ovarian autologous PRP or gonadotropin treatment and will be followed for three consecutive cycles.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome (PCOS) | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autologous Platelet-Rich Plasma (PRP) | Biological | — | UNRESOLVED |
| Gonadotropin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intra-Ovarian Autologous PRP
- description
- Participants will receive intra-ovarian autologous platelet-rich plasma (PRP) by laparoscopy and will be followed for ovarian response, ovulation, and pregnancy outcomes for three consecutive cycles
- interventionNames
- Biological: Autologous Platelet-Rich Plasma (PRP)
- type
- ACTIVE_COMPARATOR
- label
- Gonadotropin
- description
- Participants will receive gonadotropin treatment for three consecutive cycles and will be followed for ovarian response, ovulation, and pregnancy outcomes.
- interventionNames
- Drug: Gonadotropin
Primary outcomes (4)
- measure
- Proportion of Participants With Developing Follicles ≥14 mm
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 18-35 years diagnosed with polycystic ovary syndrome (PCOS) based on the Rotterdam criteria. * Primary or secondary subfertility. * Patients with a history of letrozole resistance (failure to ovulate with standard dose of letrozole). Exclusion Criteria: * Body Mass Index (BMI) \<18.5 kg/m² or ≥30 kg/m². * Presence of other causes of infertility (e.g., endometriosis, tubal factor, severe male factor infertility). * Patients with uncontrolled endocrine disorders (e.g., thyroid dysfunction, hyperprolactinemia). * Any contraindication to platelet-rich plasma (PRP) therapy (coagulation disorder or current use of anticoagulant). * Patient not fit for surgery. * Hypersensitivity to gonadotropin.
References
Publications (0)
Data not yet available